Compound A, a Ginger Extract, Significantly Reduces Pressure Overload-induced Systolic Heart Failure in Mice

Register or Login to View PDF Permissions
Permissions× For commercial reprint enquiries please contact Springer Healthcare:

For permissions and non-commercial reprint enquiries, please visit to start a request.

For author reprints, please email
Information image
Average (ratings)
No ratings
Your rating



Published online:

Open Access:

This work is open access under the CC-BY-NC 4.0 License which allows users to copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly.

Objectives: Cardiac remodelling is a compensatory mechanism associated with cardiomyocyte hypertrophy and cardiac fibrosis. This process eventually results in chronic heart failure. In this study, we screened a natural compound library for compounds that suppress both hypertrophic and fibrotic responses, and found compound A, a ginger extract. The purpose of this study is to investigate the effect of compound A on cardiomyocyte hypertrophy, cardiac fibrosis and the development of heart failure.

Materials and methods: First, primary cultured cardiomyocytes and cardiac fibroblasts were treated with 1 µM compound A, then stimulated with phenylephrine or transforming growth factor-β (TGF-β), respectively. Immunofluorestaining and qPCR were performed on cardiomyocytes. Measurement of L-proline incorporation, qPCR and western blotting were carried out on cardiac fibroblasts. C57BL/6J mice were subjected to transverse aortic constriction (TAC) surgery, then given a daily oral administration of 1 mg/kg compound A for 8 weeks. Echocardiographic analysis and measurement of heart weight to body weight (HW/BW) ratio were performed.

Results: In cultured cardiomyocytes, 1 µM of compound A suppressed phenylephrine-induced increases in the surface area of cardiomyocytes and in the mRNA levels of ANF and BNP. In cultured cardiac fibroblasts, the compound also suppressed TGF-β-induced L-proline incorporation, and mRNA and protein levels of α-smooth muscle actin. In heart failure model mice, echocardiographic analysis showed that 1 mg/kg of compound A prevented a TAC-induced increase in posterior wall thickness and a decrease in systolic dysfunction. The compound also suppressed a TAC-induced increases in HW/BW ratio.

Conclusion: Compound A may be an effective agent for heart failure therapy.